Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Amidst the turmoil, pharma stocks have taken a hit. But a POLITICO review of stock trading by lawmakers found that many, ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that scientific and commercial team leaders will host a virtual investor event where they will give an overview ...

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

Corrections & Amplifications for the edition of June 24, 2025 ...

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints.

These four BofA Securities Growth 10 stocks come with reliable dividends and are are timely ideas for growth and income ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

South Korea's Dongjin Semichem has licensed its OLED material patents to major companies, including Germany's Merck and Japan ...